Aardvark Therapeutics (AARD) Short-term Investments (2024 - 2026)

Aardvark Therapeutics has reported Short-term Investments for 3 years, with the latest figure at $28.8 million in Q1 2026.

• Quarterly Short-term Investments fell 76.94% year-over-year to $28.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $28.8 million (down 76.94% YoY) and the FY2025 annual result came in at $63.0 million, up 423.84% from the prior year.
• Short-term Investments retreated to $28.8 million in Q1 2026 per AARD's latest filing, from $63.0 million in the prior quarter.
• Over five years, Short-term Investments peaked at $124.8 million in Q1 2025 and troughed at $12.0 million in Q4 2024.
• A 3-year average of $71.9 million and a median of $75.0 million in 2025 frame the typical range for Short-term Investments.
• The sharpest annual moves came in 2025 and 2026: Short-term Investments jumped 423.84% in 2025, then tumbled 76.94% in 2026.
• Over 3 years, Short-term Investments stood at $12.0 million in 2024, then surged by 423.84% to $63.0 million in 2025, then plunged by 54.33% to $28.8 million in 2026.
• According to Business Quant data, Short-term Investments over the past three periods registered $28.8 million, $63.0 million, and $87.1 million for Q1 2026, Q4 2025, and Q3 2025 respectively.